NDT vs Slow Release T3 — Natural Desiccated Thyroid Compared

Natural desiccated thyroid has experienced a resurgence in popularity over the past two decades. Patients who felt failed by levothyroxine-only treatment turned to NDT brands like Armour Thyroid, NP Thyroid, and ERFA Thyroid as alternatives that promised a more "complete" thyroid hormone replacement. The reasoning was intuitive: if the thyroid gland produces both T4 and T3, why not take a medication derived from an actual thyroid gland?

That reasoning is not wrong on its face. NDT does contain both hormones. But the conversation has matured considerably since the early days of patient advocacy forums promoting desiccated thyroid as a universal solution. Today, a growing number of clinicians and patients are recognising that NDT vs T3 is not a matter of one being categorically superior. It is a question of pharmacology, individual physiology, and whether the fixed-ratio hormone blend in NDT actually matches what your body needs.

This article examines the evidence on both sides. If you are considering NDT or are already taking it and wondering whether pure slow release T3 might serve you better, the comparison that follows should help clarify the decision.

What Is Natural Desiccated Thyroid?

Natural desiccated thyroid (NDT) is a prescription thyroid medication derived from the dried (desiccated) thyroid glands of pigs. It has been in clinical use since the late 1800s, making it one of the oldest pharmaceutical treatments for hypothyroidism. NDT contains a mixture of thyroid hormones naturally present in porcine thyroid tissue, including thyroxine (T4), triiodothyronine (T3), diiodothyronine (T2), monoiodothyronine (T1), and calcitonin.

The primary brands available to Canadian patients include:

ERFA Thyroid is the only NDT product with a Drug Identification Number (DIN) in Canada. Manufactured by ERFA Canada, it is available in 30 mg (1/2 grain), 60 mg (1 grain), and 125 mg (2 grain) tablets. ERFA has historically been the default NDT choice for Canadian prescribers, though its availability has been inconsistent in recent years.

Armour Thyroid is the most widely recognised NDT brand in North America. Manufactured by AbbVie (formerly Forest Pharmaceuticals), it is available in multiple strengths. Canadian patients can access Armour through special importation, though it is not officially marketed in Canada.

NP Thyroid is manufactured by Acella Pharmaceuticals and has gained market share in the United States. It has faced its own consistency challenges, including a 2020 recall of certain lots due to superpotency.

Each grain (approximately 60 mg) of standard NDT provides roughly 38 micrograms of T4 and 9 micrograms of T3. These proportions are important and form the basis of the most significant criticism of NDT as a thyroid replacement strategy.

The T3:T4 Ratio Problem

The central pharmacological issue with NDT is that pig thyroid glands do not produce hormones in the same ratio as the human thyroid. The human thyroid gland produces T4 and T3 at an approximate ratio of 14:1 to 17:1. Porcine thyroid tissue, and therefore NDT, delivers these hormones at a ratio of approximately 4.2:1 (T4:T3).

This means that relative to the amount of T4 in each dose, NDT contains roughly three to four times more T3 than what the human thyroid naturally secretes. Research by Jonklaas et al. (2014) confirmed this disproportionate ratio and identified it as a key concern in clinical practice. Patients taking NDT receive a supraphysiological dose of T3 relative to T4 with every tablet.

The consequences of this imbalanced ratio are not trivial:

T3 peaks and troughs. Because T3 has a short half-life (approximately 18 to 24 hours, with peak serum levels occurring 2 to 4 hours after ingestion), the bolus of T3 delivered by each NDT dose creates a spike-and-decline pattern. Patients often feel an energy surge shortly after taking their NDT, followed by a decline as serum T3 levels fall. This roller-coaster effect can manifest as heart palpitations, anxiety, or a wired-then-crashed sensation throughout the day.

Suppressed TSH without adequate T4. The excess T3 in NDT tends to suppress TSH more aggressively than the equivalent amount of T4 alone. This can create a paradox where blood work appears to show overtreatment (low or suppressed TSH) while the patient still experiences hypothyroid symptoms, because T4 levels are lower than they would be on levothyroxine monotherapy. Clinicians unfamiliar with NDT pharmacokinetics may reduce the dose in response to suppressed TSH, leaving the patient undertreated.

Impaired T4-to-T3 conversion feedback. The body's deiodinase system is designed to regulate intracellular T3 levels by converting T4 as needed. When exogenous T3 is delivered in excess, this regulatory system is partially bypassed. Tissues that rely on local T4-to-T3 conversion, including the brain, may not receive optimal hormone levels even when serum T3 appears adequate.

For patients who respond well to NDT, these pharmacological concerns may not produce noticeable symptoms. But for those who have tried NDT and experienced jitteriness, heart palpitations, or a pattern of feeling good for a few hours followed by fatigue, the T3:T4 ratio is often the explanation.

NDT Consistency Issues

Beyond the inherent ratio problem, NDT has been plagued by consistency and supply issues that undermine patient confidence and clinical outcomes.

The Armour Thyroid reformulation of 2009 remains one of the most significant events in thyroid patient history. Forest Pharmaceuticals changed the inactive ingredients in Armour Thyroid, and thousands of patients reported a dramatic decline in efficacy. Symptoms of hypothyroidism returned in patients who had been stable on Armour for years. While the manufacturer maintained that the active hormone content was unchanged, the reformulated tablets appeared to have altered dissolution and absorption characteristics. Many patients never regained the same response after the reformulation.

NP Thyroid recalls have added to the narrative of NDT unreliability. In 2020, Acella Pharmaceuticals recalled multiple lots of NP Thyroid after testing revealed that some tablets contained more active ingredient than specified, a condition known as superpotency. Patients on these lots may have been inadvertently exposed to higher-than-prescribed doses of thyroid hormones, with all the attendant risks of overtreatment.

ERFA Thyroid availability in Canada has been intermittent. Canadian patients have reported periods where ERFA was difficult to obtain from pharmacies, forcing them to switch brands or import alternatives. For a medication that requires consistent daily dosing and where even minor variations in potency can produce symptoms, supply disruptions are more than an inconvenience. They are a clinical problem.

The underlying issue is that NDT is a biological product. Unlike synthetic pharmaceuticals, which are manufactured to exact chemical specifications, NDT is derived from animal tissue. While manufacturers standardise the final product to meet USP (United States Pharmacopeia) potency requirements, batch-to-batch variation is inherent to biological sourcing. The USP standard allows a potency range of 90 to 110 percent of the labelled hormone content, meaning that a patient switching from one batch to another could experience up to a 20 percent difference in the actual dose of T3 and T4 they receive.

For a hormone with the potency and narrow therapeutic index of T3, a 20 percent variation is significant.

Why Pure Slow Release T3 May Be Better

Slow release T3 (sustained-release liothyronine) addresses several of the pharmacological limitations that make NDT problematic for a subset of thyroid patients. Rather than delivering T3 as part of a fixed-ratio porcine hormone blend, slow release T3 provides pure, pharmaceutical-grade triiodothyronine in a matrix designed to release the hormone gradually over several hours.

The advantages of this approach are substantial:

Precise dosing. Each SRT3-15 capsule contains exactly 15 mcg of T3 with no accompanying T4, T2, T1, or calcitonin. For patients already taking levothyroxine (T4), this allows the clinician to titrate T3 independently without the confounding variable of additional T4. If your levothyroxine is not working adequately, adding a defined amount of T3 is far more controllable than switching to a product that changes both your T3 and T4 intake simultaneously.

No T3 spike. The sustained-release formulation releases T3 gradually rather than as a bolus. This avoids the peak-and-trough pattern that characterises both immediate-release T3 (Cytomel) and the T3 component of NDT. Patients report more stable energy levels, reduced palpitations, and fewer episodes of the wired-then-crashed sensation common with NDT.

No biological variability. Slow release T3 is a synthetic compound manufactured to pharmaceutical specifications. There are no batch-to-batch potency variations driven by the biological source material, no reformulation controversies, and no supply chain disruptions tied to animal sourcing.

Compatibility with existing T4 therapy. Most hypothyroid patients in Canada are already on levothyroxine. Adding slow release T3 to an existing T4 regimen allows patients and clinicians to create a customised T4:T3 ratio that matches the individual's needs rather than being locked into the 4.2:1 ratio dictated by porcine thyroid physiology. A lower dose option, SRT3-7.5, is also available for patients who need gentler T3 supplementation or more granular dose adjustments.

Relevant for hormonal transitions. Women experiencing thyroid and menopause interactions often need precise T3 adjustments as oestrogen levels shift. The ability to modify T3 dosing independently of T4 is particularly valuable during perimenopause and menopause, when thyroid hormone requirements can change significantly over relatively short periods.

Comparison Table

When NDT Makes Sense vs When SRT3 Makes Sense

Neither NDT nor slow release T3 is the correct choice for every patient. The decision depends on individual clinical circumstances, treatment history, and how well each approach addresses the specific hormonal deficit.

NDT may be the better choice when:

• The patient has never taken levothyroxine and wants a single-tablet solution providing both T4 and T3.
• The patient has a documented history of responding well to NDT with stable labs, consistent energy, and no palpitations or T3-related symptoms.
• The patient cannot tolerate synthetic levothyroxine due to excipient sensitivities and needs an alternative T4 source. Some patients report better tolerance of the T4 in NDT compared to synthetic formulations, though this is likely related to inactive ingredients rather than the hormone itself.
• The patient prefers a product with a long clinical history and is comfortable with the fixed T3:T4 ratio.

Slow release T3 may be the better choice when:

• The patient is already on levothyroxine and needs to add T3 without disrupting their established T4 dose. This is the most common clinical scenario for T3 supplementation and the one where SRT3 has the clearest advantage.
• The patient has tried NDT and experienced palpitations, anxiety, afternoon crashes, or other symptoms consistent with T3 spiking from the immediate-release T3 component.
• The patient requires precise T3 dose titration, particularly during hormonal transitions like menopause or postpartum recovery, where T3 needs may shift over weeks or months.
• The patient has a history of sensitivity to T3 and needs the smallest effective dose. The SRT3-7.5 provides 7.5 mcg in a sustained-release format, allowing very conservative initiation.
• The patient has elevated reverse T3 (rT3) levels, suggesting impaired T4-to-T3 conversion. In this scenario, adding more T4 via NDT is counterproductive; direct T3 supplementation bypasses the conversion bottleneck entirely.
• The patient's clinician wants to monitor the effect of T3 independently, without the confounding variable of simultaneously changing both T4 and T3 intake.

Frequently Asked Questions

Can I switch directly from NDT to slow release T3?

Switching from NDT to slow release T3 requires clinical guidance because you are removing both the T3 and the T4 component of your current medication. In most cases, the transition involves starting levothyroxine to replace the T4 previously supplied by NDT, then adding slow release T3 at a dose corresponding to the T3 content of your previous NDT dose. For example, if you were taking 2 grains (120 mg) of NDT, you were receiving approximately 18 mcg of T3 and 76 mcg of T4. Your clinician might start you on 75 mcg of levothyroxine plus one SRT3-15 capsule daily, then adjust based on labs and symptoms after 6 to 8 weeks.

Is NDT more "natural" than slow release T3?

NDT is derived from a natural source (porcine thyroid glands), but the concept of "natural" does not automatically confer clinical superiority. Pig thyroid glands evolved to serve pig physiology, not human physiology. The T3:T4 ratio in porcine tissue does not match human thyroid output. Slow release T3 delivers biologically identical triiodothyronine, the same molecule your thyroid produces, in a dosing format designed for human pharmacokinetics. The hormone itself is identical regardless of source; the delivery method and ratio are what differ.

Why does my doctor hesitate to prescribe T3 at all?

Many physicians were trained during an era when T3-containing therapies were considered unnecessary or dangerous. The prevailing endocrinology guidelines have historically favoured levothyroxine monotherapy based on the assumption that peripheral conversion of T4 to T3 is sufficient for all patients. This position has been challenged by research showing that a significant subset of hypothyroid patients, including those with deiodinase polymorphisms (DIO2 gene variants), do not convert T4 to T3 efficiently. The 2013 study by Hoang et al. demonstrated that patients on desiccated thyroid extract lost more weight and reported a preference for DTE over levothyroxine, with no adverse effects. If your levothyroxine is not working, this evidence supports the case for T3 supplementation.

How do I know if my NDT dose is causing T3 spikes?

The most reliable method is to test free T3 levels at multiple time points after your NDT dose. A blood draw 2 to 3 hours post-dose captures the peak, while a draw at 8 to 12 hours captures the trough. If the difference between peak and trough is large, you are experiencing significant T3 fluctuation. Symptomatically, T3 spiking often presents as a burst of energy or restlessness 1 to 3 hours after taking NDT, followed by fatigue, brain fog, or a sense of "crashing" in the afternoon. Heart palpitations shortly after dosing are another common indicator. Switching to a sustained-release T3 formulation flattens this curve considerably.

Is slow release T3 available in Canada without a prescription?

Availability depends on the specific product and source. Some compounding pharmacies in Canada can prepare sustained-release T3 with a prescription. The SRT3-15 and SRT3-7.5 formulations available through chronic-illness.ca provide Canadians with access to pharmaceutical-grade slow release T3. If you are currently managing your thyroid health in Canada and are exploring options beyond levothyroxine or NDT, these products offer a consistent and precisely dosed alternative.